Comparative hepatotoxicity and clastogenicity of sodium arsenite and three petroleum products in experimental Swiss Albino Mice: The modulatory effects of Aloe vera gel

Toxicity associated with repeated administration of artemether-lumefantrine in rats

Chemotherapy remains an important approach in the fight against malaria. Artemether-lumefantrine combination is widely in use due to its effectiveness against Plasmodium falciparum. Misuse in the form of multiple repeated doses of this anti-malaria drug is rampant in Nigeria. This study was designed to assess the hepatotoxic and clastogenic potential of extreme misuse of artemether-lumefantrine in rats. Graded doses of artemether-lumefantrine (1-5 mg/kg body weight) were administered by oral gavage for 6 weeks, twice daily, for 3 consecutive days per week. Artemether-lumefantrine, at all doses, did not have significant effects on the body and relative liver weight of treated group compared to the negative control group. The mean γ-glutamyltransferase, alanine, and aspartate aminotransaminase activity in groups of artemether-lumefantrine treated rats were significantly higher (p < 0.05) than that of the negative control group indicating that repeated administration of artemether-lumefantrine may be hepatotoxic. Findings from histological analyses of liver cross-section support the enzyme pattern of hepatoxicity. In addition, the drug, at all experimental doses, significantly induced (p < 0.05) formation of micronucleated polychromatic erythrocytes in the bone marrow cells of the treated rats compared with the negative control indicating clastogenic potential of the drug when misused.

Hepatoprotective potential of Aloe vera polysaccharides against chronic alcohol-induced hepatotoxicity in mice

BACKGROUND

Aloe vera polysaccharides are reported to exhibit multiple biological effects, including anti-oxidation, anti-inflammation and immune enhancement. However, their influence on alcoholic liver disease (ALD) remains unclear. This study was designed to determine the protective effect of extracted A. vera polysaccharides (AVGP) against ALD in a chronic alcohol-feeding mouse model and investigate the possible underlying mechanisms.

RESULTS

Supplementation of AVGP significantly attenuated the levels of serum aminotransferases, lipids and hepatic TG and ameliorated histopathological alterations in the model of ALD. Interestingly, AVGP markedly up-regulated hepatic expression of lipolytic genes (AMPK-α2 and PPAR-α) but had no effect on lipogenic gene expression. AVGP diminished alcohol-dependent oxidative stress partly through a decrease in MDA and increase in GSH and SOD. Alcohol-induced inflammation was also mitigated by AVGP treatment via significant reduction in LPS and TNF-α, down-regulation of TLR-4 and MyD88 and up-regulation of IκB-α.

CONCLUSION

This study clearly showed that AVGP exerts a potent protective effect against chronic alcohol-induced liver injury. Its hepatoprotective effect appears to be associated with its antioxidant capacity and its ability to accelerate lipolysis and inhibit inflammatory response. The results indicate that AVGP could be considered as a potent food supplement in the prevention of ALD.

Aloe vera improves memory and reduces depression in mice

OBJECTIVE

Aloe vera (barbadensis Mill., Family Liliaceae) since ancient times has been used for the treatment of skin disorders, infection, and as a laxative. The present study was undertaken to explore the effect of A. vera (Family Liliaceae) in animal models of learning and memory, depression, and locomotion.

METHODS

To assess learning and memory, the passive avoidance task and elevated plus-maze were used. For evaluating depression, the forced swim test and tail suspension test were performed, and to assess locomotor activity, the rota rod test and photoactometer were used.

RESULTS

A. vera (200 and 400 mg/kg, p.o.) was found to significantly increase the acquisition and retention step-down latency as compared to control in the passive avoidance task. In the elevated plus-maze, the highest administered dose (400 mg/kg, p.o.) of A. vera significantly reduced the transfer latency as compared to control. The forced swim test as well as tail suspension test showed that A. vera at all administered doses (100, 200, and 400 mg/kg, p.o.) decreased the period of immobility significantly. However, the locomotor activity did not show any significant change in the rota rod test and photoactometer.

DISCUSSION

Thus from the above observations, it can be proposed that A. vera enhances learning and memory, and also alleviates depression in mice.

Antifibrotic effect of aloe vera in viral infection-induced hepatic periportal fibrosis

AIM: To investigate the anti-oxidative and anti-fibrotic effects of aloe vera in patients with liver fibrosis.

METHODS: Aloe vera high molecular weight fractions (AHM) were processed by patented hyper-dry system in combination of freeze-dry technique with microwave and far infrared-ray radiation. Fifteen healthy volunteers as the control group and 40 patients were included. The patients were randomly subdivided into two equal groups: the conventional group was treated with placebo (starch), and AHM group was treated with 0.15 gm/d AHM, both for 12 consecutive weeks. The patients were investigated before and after treatment. Serum activity of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), hyaluronic acid (HA), transforming growth factor-β (TGF-β) and matrixmetalloproteinase-2 (MMP-2) were determined. The reduced glutathione (GSH) and malondialdehyde (MDA) levels in liver were assayed and the expression of hepatic α-smooth muscle actin (α-SMA) was identified by immunohistochemistry.

RESULTS: At the start of the study, the hematoxylin and eosin staining revealed fibro-proliferated bile ductules, thick fibrous septa and dense inflammatory cellular infiltration in the patients before treatment. The use of AHM for 12 wk significantly ameliorated the fibrosis, inhibited the inflammation, and resulted in minimal infiltration and minimal fibrosis compared to the conventional group. The enzyme activities of the liver (ALT, AST and ALP) were attenuated after treatment in both groups, and the decrease in the AHM group was more significant as compared with the conventional group. Similar to the AST, the MDA levels were significantly higher before treatment, and were attenuated after treatment in both groups. In contrast, the hepatic glutathione content in the patients were decreased significantly in the AHM group compared to the controls. The serum levels of the fibrosis markers (HA, TGF-β and MMP-2) were also reduced significantly after treatment. The expression of α-SMA was modified in patients before and after treatment as compared with the normal controls. In the conventional group, there was only thin and incomplete parenchymal α-SMA positive septum joining the thickened centrilobular veins, while in the AHM group, few α-SMA positive cells were present in sinusoid and lobule after treatment.

CONCLUSION: Oral supplementation with AHM could be helpful in alleviating the fibrosis and inflammation of hepatic fibrosis patients.